Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nmra · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.00
Consensus
$7.00
+333.4% upside
Low
$6.00
Median: $7 · Last Close: $1.61
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$7.00
333.4% upside
High Target
$8
395.4%
Low Target
$6
271.5%
Current Price
$1.61
as of today
Based on analyst price targets, the NMRA stock price prediction for the next 12 months ranges from $6 to $8. The consensus NMRA price forecast of $7.00 implies 333.4% upside from the current price of $1.61.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.56 | ↓ 3.21% |
1-day model range: $1.52–$1.6. Peak: $1.6 (-3.21%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -63.7% |
| 2029 | — | -69.2% |
| 2030 | — | -71.8% |
| 2031 | — | -73.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NMRA · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-31 | Guggenheim | Maintains | Buy→Buy |
| 2026-03-31 | Needham | Maintains | Buy→Buy |
| 2026-02-17 | William Blair | Upgrade ↑ | Market Perform→Outperform |
| 2025-12-01 | RBC Capital | Upgrade ↑ | Sector Perform→Outperform |
| 2025-11-17 | Stifel | Maintains | Hold→Hold |
| 2025-10-28 | Needham | Maintains | Buy→Buy |
| 2025-10-27 | Guggenheim | Upgrade ↑ | Neutral→Buy |
| 2025-09-16 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2025-07-16 | Mizuho | Maintains | Outperform→Outperform |
| 2025-05-13 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Neumora Therapeutics, Inc. Common Stock (NMRA) stock. Of the recent 35 rating actions, 3 were upgrades and 5 were downgrades. 9 analysts currently cover NMRA.
Analyst Recommendation Trends
NMRA analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 99.1% YoY
Revenue Next Year
$6M
↑ 842.5% YoY
EPS This Year
$-0.96
EPS Next Year
$-0.89
↓ 7.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast NMRA EPS of $-0.96 for the current fiscal year, based on estimates from 7 analysts. The NMRA revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NMRA stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NMRA price target is $7.00 (+333.4% upside), with an analyst consensus of Buy.
The NMRA short-term stock prediction for tomorrow is $1.56 (-3.21%). The NMRA stock prediction for 2030 projects a range of $0–$1.
Neumora Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker NMRA. The NMRA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
NMRA forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month NMRA price target is $7.00, with a high forecast of $8.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +333.4% potential upside from the current price of $1.61.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.